First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use.
about
Aminoglycosides: activity and resistance.Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa.Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populationsPharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.Once-daily aminoglycosides in patients with neutropenic fever.In vitro characterization of aminoglycoside adaptive resistance in Pseudomonas aeruginosa.Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenemAdaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis modelRationale behind high-dose amoxicillin therapy for acute otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies.Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia.Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children.Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious DiseasesAminoglycoside resistance in Pseudomonas aeruginosa.Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated EfficacyTherapeutic drug monitoring of aminoglycosides in neonates.Pharmacological considerations for the proper clinical use of aminoglycosides.Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance.Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.Aminoglycoside-induced nephrotoxicity.Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides.Influence of pH on adaptive resistance of Pseudomonas aeruginosa to aminoglycosides and their postantibiotic effects.Pharmacokinetic and pharmacodynamic approach for comparing two therapeutic regimens using amikacin.Time-survival studies for quantifying effects of azlocillin and tobramycin on Pseudomonas aeruginosaAdaptive resistance following single doses of gentamicin in a dynamic in vitro model.Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants.Preclinical and clinical evaluation of once-daily aminoglycoside chemotherapy.The place of tobramycin in lower respiratory tract infections (LRTI).Systemic antibiotic therapy in periodontics.Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.Studies on drug monitoring in thrice and once daily treatment with aminoglycosides.Ceftazidime, gentamicin, and rifampicin, in combination, kill biofilms of mucoid Pseudomonas aeruginosa.Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate?Efficacy and safety of once-daily amikacin in combination with ceftazidime in critically ill adults with severe gram-negative infections.
P2860
Q33548221-14A0A972-A9C3-4715-838A-03BD43FFEA08Q33693985-EB4AF3D8-0F0C-455C-8961-2E108B3C09B6Q33722011-BB2F1CEE-4D7F-420F-B179-C1815958B625Q33976236-B873D4B1-DC31-4BDA-8DEB-CE0DD271BA93Q34985783-DAD7BCBF-4E19-4D82-952B-FE1D25098C4CQ35124853-F75263D0-B60A-4184-B874-76A9AB1E1097Q35132306-79BFF0B7-A56C-4063-9778-6300E138D522Q35135145-167C1370-7F9D-40C0-A512-08AA6036D6CFQ35138044-BCA7E6A4-EBBB-4ED4-8B32-9F0C609A1C7BQ35262273-82C412F2-9F1A-4729-B77E-38C4745AE554Q35885240-7F74F5AB-ACAA-442C-90DE-E0EF139D5568Q35986250-7B31E972-1933-4DB3-BF65-027F42526510Q36021296-5E503229-AAD1-456C-8E99-4CEE3E9CB516Q36290620-4434053D-F75D-4C8C-A1C1-CB53C39A904BQ37409465-CA397E5C-DBCF-4A7E-8584-39F392E5C71FQ37956403-DF166F69-F2BD-45B6-BBBC-86ED94623673Q38049220-F3B2E3A5-8B6D-417D-8F22-A62000461AB8Q38093135-29DF1796-7D30-4732-AAF1-4C99854A8A2AQ38246945-8E8C4D48-CC53-4668-9C45-5E56A45D97B7Q38626980-277D90D2-38ED-4A2F-83EE-2D0E1073F7B9Q39743310-8C943605-497B-4B3C-8809-1407DC53822AQ39781139-C4D92AD3-7C65-4F18-A9A6-D55AC0E7B06AQ39866827-4F631498-FF89-4E58-B1D8-43E5CB9C57A5Q39867055-C224C72F-C9A3-4F7A-8EDD-8A867AE195D6Q39881843-12E565C9-94E1-4EBF-9C32-96E65D9A4B83Q40326667-D80F8981-26AE-408E-B43A-69A9F06161FDQ40949882-81773FCF-9224-49BA-B0FA-752AF52D2090Q40949894-746D2E82-096E-4622-A844-3FF9E95CE656Q41754764-20BF50A6-6549-4094-88EA-121B79E3D799Q42717931-35DDCC47-5461-4E8C-82C6-7FA345F671ECQ43716998-568DF8C1-4A68-4FB9-A2EF-EB326A9E3684Q43863672-2498F741-62DC-484A-BB2D-AC2A4D8CE3E1Q43872720-FF9E7BDC-DE48-4CFE-9D0A-E2D18FF2959BQ54576022-D52F22A5-CA48-4045-9FB1-B748C9257485
P2860
First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
First-exposure adaptive resist ...... ning for optimal clinical use.
@en
type
label
First-exposure adaptive resist ...... ning for optimal clinical use.
@en
prefLabel
First-exposure adaptive resist ...... ning for optimal clinical use.
@en
P2093
P2860
P356
P1476
First-exposure adaptive resist ...... ning for optimal clinical use.
@en
P2093
P2860
P304
P356
10.1128/AAC.35.1.117
P407
P577
1991-01-01T00:00:00Z